OR
Organogenesis Holdings Inc.
ORGO · NASDAQ
$1.33 -5.00% (-$0.07)
1M -16.17%
Market Cap $180.1M
P/E Ratio -
Div. Yield -
ROE 24.23%
Bulios Fair Price
$1.01
24.1% downside
Current Price
$1.33
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ORGO is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
2/9Valuation
100 /100
Cheap P/FCF 8.64x
P/S 0.39x
PEG 0.00x
Growth
61 /100
Stable Book val. growth 17.77%
EPS growth 7.72%
Rev. growth 7.68%
Profitability
31 /100
Weak Op. margin 6.38%
Gross margin 67.59%
FCF margin 4.56%
Quality
14 /100
Poor ROA 22.20%
ROIC 20.37%
Asset turnover 1.12x
Debt
100 /100
Low Current ratio 3.52x
Debt/Equity 0.23x
Debt/Assets N/A
Stability
55 /100
Moderate EPS volatility 980.69%
Beta 1.29x
Profitable years 6
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ORGO
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Gary S. Gillheeney
Employees
854
Headquarters
Canton
Upcoming events
05 NOV
Earnings
Upcoming earnings report